Minuteman Therapeutics
Minuteman Therapeutics is an early-stage company developing personalized oncolytic viruses, viruses designed to infect and break down cancer cells, matched to the biology of an individual patient's tumor.
- Approach
- Personalized oncolytic viruses matched to the biology of an individual patient's tumor.[1]
- Stage
- Early stage. The site lists no clinical trial, price or availability as of October 24, 2026.[1]
- How to start
- Email the company through the contact on its site.[1]
- Backer
- Part of the Even One Ventures portfolio.[2]
Approach
StageMinuteman Therapeutics is an early-stage company building personalized oncolytic viruses for cancer. Its site describes the goal as viruses matched to the biology of an individual patient's tumor. It is part of the Even One Ventures portfolio, a group of companies started to make scientific advances reach patients faster.
What it is working on
Oncolytic viruses are viruses designed to infect cancer cells, replicate inside them and break those cells down as they spread. Minuteman's site says that, in principle, they can do two things at once: attack the tumor directly and recruit the immune system against it.
The site notes that most viral therapies have been built as fixed products for broad groups of patients. Minuteman says it is taking a different path, with oncolytic virus approaches matched to one person's tumor.
Where it stands
This is early. As of October 24, 2026, the site does not list a clinical trial, a price, eligibility rules or a date when patients could receive a treatment. I would treat it as a company to follow and ask questions of, not a treatment you can sign up for today.
How to start
The site invites patients to email the company, and says it will be in touch. Bring a short summary of your diagnosis and treatment history if you reach out.
How it fits
Like Echo Immune and Serova, Minuteman is working on a treatment built around one patient's tumor. Those two make personalized vaccines; Minuteman is working with viruses. If you are exploring options like these, Clinical trials and Tumor testing explain the groundwork that usually comes first, and Personalized cancer vaccines: what to ask has questions that apply to other personalized approaches too.
Questions I would ask
- Is anything open to patients now, such as a study or an expanded access path?
- What information about my tumor would you need, and would existing sequencing be enough?
- How would my oncologist be involved?
- What safety data exists so far for your approach?
- What would it cost, and who would pay?
Contacts
- Website: minuteman.bio
- Email: hello@minuteman.bio
Services & community focus
Company
